#USA #San Diego #Olverembatinib #CML #Ascentage

Breakthrough in CML Treatment: Olverembatinib as a Second-Line Therapy

At the recent 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California, Ascentage Pharma unveiled compelling clinical data demonstrating the efficacy of olverembatinib (HQP1351) as a second-line treatment option for patients diagnosed with non-T315I-mutant chronic phase chronic myeloid leukemia (CP-CML). Prof. Weiming Li from Wuhan Union Hospital presented this data, highlighting the promising potential of olverembatinib in a population where existing treatment options may have fallen short.

Efficacy Data Insights

The preliminary findings showcase the first dataset of olverembatinib in this context, revealing significant response rates. Among patients who had previously shown resistance or intolerance to at least one line of tyrosine kinase inhibitors (TKIs), notable responses were observed – a complete cytogenetic response (CCyR) reached 74.1% and a major molecular response (MMR) attained 40.6%. Moreover, patients who had been treated with second-generation TKIs previously reported even better statistics of 78.9% for CCyR and 43.5% for MMR.

These results imply that olverembatinib could represent a vital therapeutic avenue for patients who struggle to succeed with first-line treatments. This groundbreaking achievement marks the seventh consecutive year olverembatinib has been recognized at the ASH annual meeting with oral presentations, a testament to its enduring significance in the hematology landscape.

Safety Profile

The safety profile of olverembatinib was also elaborated upon, maintaining a favorable safety record consistent with previous studies. Importantly, the presentation confirmed no new safety signals emerged throughout the study, with no arterial occlusive events or venous thromboembolisms reported among participants. This is encouraging as it suggests a promising safety quotient that can be vital for chronic-condition therapies, where long-term use may be necessary.

Patients involved in the study were subjected to olverembatinib orally at 40 mg every other day, escalating over 28-day cycles. During this period, the median treatment duration reached 16 months, with treatment-related adverse events reported in 95.3% of cases, mostly characterized by mild to moderate symptoms.

The Future of CML Treatments

As the first third-generation BCR-ABL inhibitor receiving approval in China, olverembatinib already holds a place in treatment regimens for adult patients demonstrating resistance or intolerance to TKIs both in chronic and accelerated phases of CP-CML. The joint commercialization efforts by Ascentage Pharma and Innovent Biologics signify aspects of demand and competitive edge in the biopharmaceutical sector in addressing specific treatment needs in this patient demographic.

Prof. Li emphasized the crucial need for enhanced second-line therapy for patients facing ineffective first-line treatment, expressing hope that olverembatinib could bridge that gap effectively. Alongside ongoing commitments, Ascentage aims to expand clinical data availability to facilitate broader health guidelines and clinical protocols regarding its usage.

Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, echoed these sentiments, reassuring stakeholders, “Our continuous presence at the ASH Annual Meeting highlights the global hematology community's interest in uncovering deeper insights into olverembatinib's potential.” Ascentage is navigating toward expedited trails and developments for its innovative therapies, jointly striving for enhanced outcomes in populations affected by cancer technologies today.

As the treatments for chronic myeloid leukemia evolve, breakthroughs such as olverembatinib provide not just new options for patients, but hope for progress in hematological malignancies' chronic battle.